- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00291759
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
January 29, 2013 updated by: AstraZeneca
Adjuvant Endocrine Therapy in Postmenopausal Patients With HR +ve BC With Good to Moderate Differentiation - ARNO (Arimidex + Nolvadex). Primary Treatment for 2 Years With Tamoxifen Thereafter Randomisation to: Tamoxifen 3 Years or Anastrozole 3 Years.
The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
3858
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amstetten, Austria
- Research Site
-
Bad Ischl, Austria
- Research Site
-
Baden, Austria
- Research Site
-
Bregenz, Austria
- Research Site
-
Bruck/Mur, Austria
- Research Site
-
Dornbirn, Austria
- Research Site
-
Eisenstadt, Austria
- Research Site
-
Feldbach, Austria
- Research Site
-
Feldkirch, Austria
- Research Site
-
Freistadt, Austria
- Research Site
-
Fuerstenfeld, Austria
- Research Site
-
Gmuend, Austria
- Research Site
-
Graz, Austria
- Research Sites
-
Guessing, Austria
- Research Site
-
Hainburg, Austria
- Research Site
-
Hartberg, Austria
- Research Site
-
Hollabrunn, Austria
- Research Site
-
Horn, Austria
- Research Site
-
Innsbruck, Austria
- Research Site
-
Judenburg, Austria
- Research Site
-
Kirchdorf, Austria
- Research Site
-
Klagenfurt, Austria
- Research Site
-
Klosterneuburg, Austria
- Research Sites
-
Kufstein, Austria
- Research Site
-
Leoben, Austria
- Research Site
-
Linz, Austria
- Research Sites
-
Melk, Austria
- Research Site
-
Mistelbach, Austria
- Research Site
-
Moedling, Austria
- Research Site
-
Neunkirchen, Austria
- Research Site
-
Oberpullendorf, Austria
- Research Site
-
Oberwart, Austria
- Research Site
-
Ried im Innkreis, Austria
- Research Site
-
Rohrbach, Austria
- Research Site
-
Rottenmann, Austria
- Research Site
-
Salzburg, Austria
- Research Site
-
Schaerding, Austria
- Research Site
-
Scheibbs, Austria
- Research Site
-
Schladming, Austria
- Research Site
-
Schwarzach/Pongau, Austria
- Research Site
-
Spittal/Drau, Austria
- Research Site
-
St. Poelton, Austria
- Research Site
-
St. Veit/Glan, Austria
- Research Site
-
Steyr, Austria
- Research Site
-
Tulln, Austria
- Research Site
-
Vienna, Austria
- Research Sites
-
Villach, Austria
- Research Site
-
Voecklabruck, Austria
- Research Site
-
Waidhofen/Thaya, Austria
- Research Site
-
Wels, Austria
- Research Site
-
Wolfsberg, Austria
- Research Site
-
Zams, Austria
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 80 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Invasive mammary carcinoma after radical treatment, without prior chemo/hormone/radiation therapy.
- At least 6 lymph nodes examined.
- Good or intermediate tumour differentiation.
- <6 weeks before start of adjuvant therapy.
- Oestrogen or Progesterone positive
Exclusion Criteria:
- Premenopausal.
- Preoperative hormonal/antihormonal/radiation/cytoxic chemo. Second malignant tumour/status post second malignant tumour.
- In-situ/T4 carcinoma.
- Age >80 years.
- World Health Organisation performance index >3.
- Serious accompanying diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
To assess the difference in event free survival and overall survival (subject to stand-alone or combined/meta-analysis) between postmenopausal women with HR +ve early BC who switched from tamoxifen to anastrozole and those who continued on tamoxifen.
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
To assess the difference in event free survival & overall survival (subject to stand-alone or combined/meta-analysis) plus side effects between postmenopausal women with HR+ve early BC who switched from tam to anastrozole and those who continued on tam.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: AstraZeneca Austria Medical Director, MD, AstraZeneca
- Principal Investigator: Raimund Jakesz, MD, Austrian Breast and Colorectal Cancer Study Group
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol. 2015 Mar 10;33(8):916-22. doi: 10.1200/JCO.2014.55.6894. Epub 2014 Oct 20.
- Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014 Feb;25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 1996
Primary Completion (Actual)
June 1, 2009
Study Completion (Actual)
June 1, 2009
Study Registration Dates
First Submitted
February 13, 2006
First Submitted That Met QC Criteria
February 13, 2006
First Posted (Estimate)
February 15, 2006
Study Record Updates
Last Update Posted (Estimate)
January 30, 2013
Last Update Submitted That Met QC Criteria
January 29, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Bone Density Conservation Agents
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Tamoxifen
- Anastrozole
Other Study ID Numbers
- 1033AU/0002
- ABCSG 8
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.